James Bolling
About James Bolling
James Bolling serves as the Senior Director at Precision BioSciences, Inc., focusing on CMC strategy and business development for in vivo gene editing programs. He has over a decade of experience in biopharmaceuticals, with expertise in biologics, cell therapy, and gene therapy.
Current Role at Precision BioSciences
James Bolling serves as Senior Director at Precision BioSciences, Inc., where he focuses on CMC strategy and business development for multiple in vivo gene editing programs. He has held this position since 2022, contributing to the advancement of gene editing technologies and their applications in biopharmaceuticals.
Professional Experience in Biopharmaceuticals
Bolling has extensive experience in the biopharmaceutical sector, having worked in various roles at Precision BioSciences, Inc. He was a Process Engineer from 2017 to 2019, followed by a role as Process Engineer II from 2019 to 2020. He later became Team Lead for Cell Therapy Process Development from 2020 to 2022 before assuming his current role as Senior Director.
Previous Experience at MedImmune
Prior to his tenure at Precision BioSciences, Bolling worked at MedImmune, where he held several positions. He served as Research and Development Associate II from 2013 to 2015 and as Associate Scientist I from 2015 to 2017. He also briefly held the role of Associate Scientist II in 2017 for three months.
Educational Background
Bolling earned a Bachelor of Science in Biology and a Bachelor of Arts in Economics from the University of Virginia. He furthered his education at Northwestern University, where he obtained a Master of Science in Biotechnology from the McCormick School of Engineering.
Expertise in Biopharmaceutical Areas
James Bolling has developed expertise in various biopharmaceutical domains, including traditional biologics, cell therapy, and gene therapy. His specific knowledge encompasses CAR-T, LNP, and AAV technologies, reflecting his comprehensive understanding of the industry's evolving landscape.